Prognostic relevance of DHAP dose-density in relapsed Hodgkin lymphoma: an analysis of the German Hodgkin-Study Group

被引：10

作者：

Sasse, Stephanie ^{[1
]}

Alram, Magdalena ^{[1
]}

Mueller, Horst ^{[1
]}

Smardova, Lenka ^{[2
,3
]}

Metzner, Bernd ^{[4
]}

Doehner, Hartmut ^{[5
]}

Fischer, Thomas ^{[6
]}

Niederwieser, Dietger W. ^{[7
]}

Schmitz, Norbert ^{[8
]}

Schaefer-Eckart, Kerstin ^{[9
]}

Raemaekers, John M. M. ^{[10
]}

Schmalz, Oliver ^{[11
]}

Tresckow, Bastian V. ^{[1
]}

Engert, Andreas ^{[1
]}

Borchmann, Peter ^{[1
]}

机构：

[1] Univ Hosp Cologne, German Hodgkin Study Grp, Internal Med 1, Kerpener Str 62, D-50937 Cologne, Germany

[2] Masaryk Univ, Univ Hosp Brno, Brno, Czech Republic

[3] Masaryk Univ, Fac Med, Brno, Czech Republic

[4] Hosp Oldenburg, Dept Hematol & Oncol, Oldenburg, Germany

[5] Univ Hosp Ulm, Clin Internal Med 3, Ulm, Germany

[6] Univ Hosp Magdeburg, Dept Hematol & Oncol, Magdeburg, Germany

[7] Univ Hosp Leipzig, Dept Hematol & Oncol, Leipzig, Germany

[8] Asklepios Clin St Georg, Oncol, Dept Hematol, Hamburg, Germany

[9] Klinikum Nuernberg Nord, Dept Oncol Hematol, Nurnberg, Germany

[10] Radboud Univ Nijmegen, Med Ctr, Dept Hematol, NL-6525 ED Nijmegen, Netherlands

[11] Helios Clin Wuppertal, Clin Internal Med 1, Wuppertal, Germany

来源：

LEUKEMIA & LYMPHOMA | 2016年 / 57卷 / 05期

关键词：

DHAP; dose density; hematotoxicity; outcome; relapsed Hodgkin lymphoma; STEM-CELL TRANSPLANTATION; CHEMOTHERAPY; DISEASE; CHEMORADIOTHERAPY; INTENSITY; SALVAGE; BEACOPP; ABVD;

D O I：

10.3109/10428194.2015.1083561

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Only 50% of patients with relapsed Hodgkin lymphoma (HL) can be cured with intensive induction chemotherapy, followed by high-dose chemotherapy (HDCT) and autologous stem cell transplant (ASCT). Based on the results of the HDR2 trial two courses of DHAP and subsequent HDCT/ASCT are the current standard of care in relapsed HL. In order to assess the prognostic relevance of DHAP dose density, we performed a retrospective multivariate analysis of the HDR2 trial (N=266). In addition to four risk factors (early or multiple relapse, stage IV disease or anemia at relapse, and grade IV hematotoxicity during the first cycle of DHAP) a delayed start of the second cycle of DHAP>day 22 predicted a significantly poorer progression-free survival (PFS, p=0.0356) and overall survival (OS, p=0.0025). In conclusion, our analysis strongly suggests that dose density of DHAP has a relevant impact on the outcome of relapsed HL patients.

引用

页码：1067 / 1073

页数：7

共 17 条

[1] Dose density in adjuvant chemotherapy for breast cancer [J].

Citron, ML .

CANCER INVESTIGATION, 2004, 22 (04) :555-568

[2] Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease [J].

Diehl, V ;

Franklin, J ;

Pfreundschuh, M ;

Lathan, B ;

Paulus, U ;

Hasenclever, D ;

Tesch, H ;

Herrmann, R ;

Dörken, B ;

Müller-Hermelink, H ;

Dühmke, E ;

Loeffler, M .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (24) :2386-2395

[3] Hodgkin's lymphoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up [J].

Engert, A. ;

Eichenauer, D. A. ;

Dreyling, M. .

ANNALS OF ONCOLOGY, 2009, 20 :108-109

[4] Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin Lymphoma Study Group [J].

Josting, A ;

Rueffer, U ;

Franklin, J ;

Sieber, M ;

Diehl, V ;

Engert, A .

BLOOD, 2000, 96 (04) :1280-1286

[5] Time-intensified dexamethasone/cisplatin/cytarabine:: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease [J].

Josting, A ;

Rudolph, C ;

Reiser, M ;

Mapara, M ;

Sieber, M ;

Kirchner, HH ;

Dörken, B ;

Hossfeld, DK ;

Diehl, V ;

Engert, A .

ANNALS OF ONCOLOGY, 2002, 13 (10) :1628-1635

[6] Dose Intensity of Chemotherapy in Patients With Relapsed Hodgkin's Lymphoma [J].

Josting, Andreas ;

Mueller, Horst ;

Borchmann, Peter ;

Baars, Joke W. ;

Metzner, Bernd ;

Doehner, Hartmut ;

Aurer, Igor ;

Smardova, Lenka ;

Fischer, Thomas ;

Niederwieser, Dietger ;

Schaefer-Eckart, Kerstin ;

Schmitz, Norbert ;

Sureda, Anna ;

Glossmann, Jan ;

Diehl, Volker ;

DeJong, Daphne ;

Hansmann, Martin-Leo ;

Raemaekers, John ;

Engert, Andreas .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (34) :5074-5080

[7] DOSE INTENSIFICATION WITH AUTOLOGOUS BONE-MARROW TRANSPLANTATION IN RELAPSED AND RESISTANT HODGKINS-DISEASE - RESULTS OF A BNLI RANDOMIZED TRIAL [J].

LINCH, DC ;

WINFIELD, D ;

GOLDSTONE, AH ;

MOIR, D ;

HANCOCK, B ;

MCMILLAN, A ;

CHOPRA, R ;

MILLIGAN, D ;

HUDSON, GV .

LANCET, 1993, 341 (8852) :1051-1054

[8] Maintaining the dose intensity of ICE chemotherapy with a thrombopoietic agent, PEG-rHuMGDF, may confer a survival advantage in relapsed and refractory aggressive non-Hodgkin lymphoma [J].

Moskowitz, C. H. ;

Hamlin, P. A. ;

Gabrilove, J. ;

Bertino, J. R. ;

Portlock, C. S. ;

Straus, D. J. ;

Gencarelli, A. N. ;

Nimer, S. D. ;

Zelenetz, A. D. .

ANNALS OF ONCOLOGY, 2007, 18 (11) :1842-1850

[9] Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin's disease [J].

Moskowitz, CH ;

Kewalramani, T ;

Nimer, SD ;

Gonzalez, M ;

Zelenetz, AD ;

Yahalom, J .

BRITISH JOURNAL OF HAEMATOLOGY, 2004, 124 (05) :645-652

[10] A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model [J].

Moskowitz, CH ;

Nimer, SD ;

Zelenetz, AD ;

Trippett, T ;

Hedrick, EE ;

Filippa, D ;

Louie, D ;

Gonzales, M ;

Walits, J ;

Coady-Lyons, N ;

Qin, J ;

Frank, R ;

Bertino, JR ;

Coy, A ;

Noy, A ;

O'Brien, JP ;

Straus, D ;

Portlock, CS ;

Yahalom, J .

BLOOD, 2001, 97 (03) :616-623

← 1 2 →